A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo

Cancer Research

Volumn 69, Issue 16, 2009, Pages 6531-6538

  Yagi, Nobuhiro ^a,b   Manabe, Ichiro ^a,c,d   Tottori, Tsuneaki ^b   Ishihara, Atsushi ^b   Ogata, Fusa ^a   Jong, Heon Kim ^a   Nishimura, Satoshi ^a   Fujiu, Katsuhito ^a   Oishi, Yumiko ^a   Itaka, Keiji ^a   Kato, Yasuki ^b   Yamauchi, Masahiro ^b   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR 5; MESSENGER RNA; NANOCARRIER; POLYMER; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DESIGN; DRUG EFFECT; DRUG HALF LIFE; DRUG RELEASE; DRUG STABILITY; DRUG TRANSPORT; ENZYMATIC DEGRADATION; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; IN VIVO STUDY; LIPID BILAYER; MALE; MOUSE; NANOPHARMACEUTICS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR MODEL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; CARBOCYANINES; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HALF-LIFE; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; NANOPARTICLES; NEOPLASMS; RNA STABILITY; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; WHOLE BODY IMAGING;

EID: 69249150822     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3945     Document Type: Article

References (18)

1. Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today 2006;11:67-73.
2. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007;117:3623-32.
3. 3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid. J Control Release 1996;41:121-30.
4. Litzinger DC, Brown JM, Wala I, et al. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim Biophys Acta 1996;1281:139-49.
5. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A 1988;85:6949-53.
6. Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 1989;6:193-210.
7. Matsumura Y, Maeda H. A new concept for macromolecular therapies in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res 1986;46:6387-92.
8. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics. J Control Release 2000;65:271-84.
9. Charrois GJR, Allen TM. Rate of biodistribution of STEALTH(R) liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta 2003;1609: 102-8.
10. Yamauchi M, Kusano H, Saito E, et al. Improved formulations of antisense oligodeoxynucleotides using wrapped liposomes. J Control Release 2006;114:268-75.
11. Aizawa K, Suzuki T, Kada N, et al. Regulation of platelet-derived growth factor-A chain by Kruppel-like factor 5. J Biol Chem 2004;279:70-6.
12. Kam W, Clauser E, Kim YS, Kan YW, Rutter WJ. Cloning, sequencing, and chromosomal localization of human term placental alkaline phosphatase cDNA. Proc Natl Acad Sci U S A 1985;82:8715-9.
13. Michelsen KS, Wong MH, Shah PK, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A 2004;101:10679-84.
14. Inaba M, Kobayashi T, Tashiro T, et al. Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose. Cancer 1989;64:1577-82.
15. Manabe I, Owens GK. Recruitment of serum response factor and hyperacetylation of histones at smooth muscle-specific regulatory regions during differentiation of a novel P19-derived in vitro smooth muscle differentiation system. Circ Res 2001;88:1127-34.
16. Fujiu K, Manabe I, Ishihara A, et al. Synthetic retinoid Am80 suppresses smooth muscle phenotypic modulation and in-stent neointima formation by inhibiting KLF5. Circ Res 2005;97:1132-41.
17. Shindo T, Manabe I, Fukushima Y, et al. Kruppellike zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med 2002;8:856.
18. Li W, Szoka FC, Jr. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res 2007;24:438-49.